[go: up one dir, main page]

EP1957064A4 - Traitement d'allongement de l'intervalle qt et maladies associees - Google Patents

Traitement d'allongement de l'intervalle qt et maladies associees

Info

Publication number
EP1957064A4
EP1957064A4 EP06827886A EP06827886A EP1957064A4 EP 1957064 A4 EP1957064 A4 EP 1957064A4 EP 06827886 A EP06827886 A EP 06827886A EP 06827886 A EP06827886 A EP 06827886A EP 1957064 A4 EP1957064 A4 EP 1957064A4
Authority
EP
European Patent Office
Prior art keywords
treatment
associated therewith
diseases associated
interval prolongation
prolongation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06827886A
Other languages
German (de)
English (en)
Other versions
EP1957064A2 (fr
Inventor
Lin Zhao
Arthur Brown
Glenn Kirsch
Antonio Lacerda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Tap Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceuticals Inc filed Critical Tap Pharmaceuticals Inc
Publication of EP1957064A2 publication Critical patent/EP1957064A2/fr
Publication of EP1957064A4 publication Critical patent/EP1957064A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EP06827886A 2005-11-21 2006-11-20 Traitement d'allongement de l'intervalle qt et maladies associees Withdrawn EP1957064A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73872405P 2005-11-21 2005-11-21
PCT/US2006/045042 WO2007062028A2 (fr) 2005-11-21 2006-11-20 Traitement d'allongement de l'intervalle qt et maladies associees

Publications (2)

Publication Number Publication Date
EP1957064A2 EP1957064A2 (fr) 2008-08-20
EP1957064A4 true EP1957064A4 (fr) 2010-01-06

Family

ID=38067855

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06827886A Withdrawn EP1957064A4 (fr) 2005-11-21 2006-11-20 Traitement d'allongement de l'intervalle qt et maladies associees

Country Status (4)

Country Link
EP (1) EP1957064A4 (fr)
JP (1) JP2009516691A (fr)
CA (1) CA2630639A1 (fr)
WO (1) WO2007062028A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504202A (ja) 2003-09-04 2007-03-01 ポセイドン ファーマシュティカルズ アクティーゼルスカブ 心臓不整脈を治療するためのｅｒｇチャネル開口薬
EP2155643B1 (fr) 2007-06-08 2016-08-10 MannKind Corporation Inhibiteurs d'ire-1a
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
IT1400310B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e statine e loro uso.
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
IT1400609B1 (it) 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
IT1400311B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso.
KR101797936B1 (ko) 2010-09-10 2017-11-15 다케다 파마슈티칼스 유에스에이, 인코포레이티드 테오필린과 페북소스타트의 병용 치료 방법
WO2012167212A2 (fr) * 2011-06-03 2012-12-06 Signpath Pharma Inc. Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
JP5924699B2 (ja) * 2012-01-27 2016-05-25 帝人ファーマ株式会社 糖尿病の治療薬
ES2787625T3 (es) * 2014-04-17 2020-10-16 Novartis Ag Activadores de hERG policíclicos
CA2950758C (fr) * 2014-06-03 2020-04-28 Signpath Pharma, Inc. Effet protecteur de dmpc, dmpg, dmpc/dmpg, egpg, lysopg et lysopc contre des medicaments provoquant des canalopathies
CN106569163A (zh) * 2015-10-08 2017-04-19 南京南瑞继保电气有限公司 一种检测互感器拖尾量的方法
KR102603673B1 (ko) 2016-04-27 2023-11-17 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
JP6954582B2 (ja) * 2016-12-22 2021-10-27 国立大学法人滋賀医科大学 医薬組成物
CN110312528B (zh) 2017-02-20 2022-02-18 国立大学法人京都大学 用于起因于剪接异常的遗传性疾病的药物组合物及治疗方法
WO2018182346A1 (fr) * 2017-03-30 2018-10-04 고려대학교 산학협력단 Composition de diagnostic ou de prédiction du syndrome du qt long induit par un médicament, kit, et procédé de diagnostic ou de prédiction de syndrome du qt long induit par un médicament l'utilisant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023238A1 (fr) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Ouvreurs du canal erg destines au traitement de maladies neuronales liees a l'hyperexcitabilite
WO2005023237A1 (fr) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Substances d'ouverture des canaux erg pour le traitement d'arythmies cardiaques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100082A2 (fr) * 2002-05-24 2003-12-04 Neurion Pharmaceuticals, Inc. Methodes permettant de determiner des interactions precises de herg et composes de modification bases sur lesdites interactions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023238A1 (fr) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Ouvreurs du canal erg destines au traitement de maladies neuronales liees a l'hyperexcitabilite
WO2005023237A1 (fr) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Substances d'ouverture des canaux erg pour le traitement d'arythmies cardiaques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANG JIESHENG ET AL: "Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.", MOLECULAR PHARMACOLOGY MAR 2005, vol. 67, no. 3, March 2005 (2005-03-01), pages 827 - 836, XP002556830, ISSN: 0026-895X *
ZHOU JUN ET AL: "Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.", MOLECULAR PHARMACOLOGY SEP 2005, vol. 68, no. 3, September 2005 (2005-09-01), pages 876 - 884, XP002556829, ISSN: 0026-895X *

Also Published As

Publication number Publication date
WO2007062028A2 (fr) 2007-05-31
JP2009516691A (ja) 2009-04-23
EP1957064A2 (fr) 2008-08-20
WO2007062028A8 (fr) 2008-05-15
WO2007062028A3 (fr) 2009-05-07
CA2630639A1 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1957064A4 (fr) Traitement d'allongement de l'intervalle qt et maladies associees
EP1968607A4 (fr) Traitement du cancer et d'autres maladies
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
IL189528A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL217839A0 (en) Pharmaceuticals compositions for the treatment of cancer and pther diseases or disorders
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
HK1171972A1 (zh) 治療疾病的方法和產品
GB0603181D0 (en) Treatment of neurodegenerative and psychiatric diseases
EP2001488A4 (fr) Prevention et traitement des cancers et d'autres maladies
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1954800A4 (fr) Composition et utilisation d'un phyto-percolate pour le traitement d'une maladie
EP1928247A4 (fr) Composition et utilisation de phyto-percolate pour le traitement d'une maladie
EP1789047A4 (fr) Procede pour traiter des maladies au moyen de nalmefene et de ses analogues
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
GB0604826D0 (en) The treatment of inflammatory disorders and pain
EP1773882A4 (fr) Diagnostic et traitement de maladies associees a siglec-6
IL185575A0 (en) Benzoxazocines and their therapeutic use
GB0526394D0 (en) Treatment of inflammatory diseases
ZA200707947B (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0604822D0 (en) The treatment of inflammatory disorders and pain
EP1846013A4 (fr) Traitement de dermatoses
GB0519274D0 (en) The treatment of neurodegenerative diseases
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080612

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120445

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20090507

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101AFI20090623BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/06 20060101ALI20091124BHEP

Ipc: A61K 31/44 20060101ALI20091124BHEP

Ipc: A61K 31/426 20060101ALI20091124BHEP

Ipc: A61K 31/00 20060101AFI20091124BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120445

Country of ref document: HK